Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Conditions:   Advanced Solid Tumors;   MSI-H/dMMR Tumors;   Cutaneous Squamous Cell Carcinoma;   Urothelial Carcinoma, HCC;   Cervical Cancer;   Esophageal Squamous Cell Carcinoma;   Merkel Cell Carcinoma, Small-cell Lung Cancer;   Mesothelioma;   PD-L1 Amplified Tumor (9p24.1);   Nasopharyngeal Carcinoma;   Cyclin-dependent Kinase 12 Mutated Tumors;   Basal Cell Carcinoma (Unresectable or Metastatic);   Sarcomatoid Renal Cell Carcinoma;   Clear Cell Ovarian or Endometrial Carcinoma;   Anal Carcinoma;   Squamous Cell Penile Carcinoma;   DNA Polym erase Epsilon Mutated Tumors (P286R and V411L) Intervention:   Drug: INCB099318 Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials